NEW YORK, Aug. 5 (GenomeWeb News) - Shamrock Structures of Woodbridge, Ill., today announced that it has signed an agreement to provide integrated structural proteomics services to Intra-Cellular Therapies.
Under the pact, Shamrock will perform structure-activity relationship co-crystallization, synchrotron data collection, and structure determination of an Intra-Cellular Therapies protein target to which inhibitors are bound. The agreement includes an upfront fee and milestone payments. Additional terms of the deal were not disclosed.
New York-based Intra-Cellular Therapies is a privately held biopharmaceutical firm developing drugs for central nervous system disorders, such as depression, schizophrenia, Alzheimer's and Parkinson's disease.